



The University of Crete Medical School

Graduate Program in Molecular Basis of Human Disease

Seminar

“Secukinumab a novel targeted IL-17A inhibitor, bench to bedside road map”

Shephard Mpofu MD FRCP

Global Program, Medical Director Integrated Hospital Care,
Novartis Pharma AG

Wednesday, December 11, 2013

10.00-12.00N

Room 7A-0.1, Post-graduate Building, Medical School

Host: P. Sidiropoulos
(Tel.4873)

Supported by the European Commission - funded program
‘Translational Potential’ (TransPOT).



TransPOT

Building Excellence in Translational Medical Research